Home

Clinical Trials

Memorial Sloan Kettering clinical trials are now available for Hartford HealthCare Cancer Institute patients.

As part of the Hartford HealthCare Cancer Institute’s pioneering membership in the Memorial Sloan Kettering (MSK) Cancer Alliance, an increasing number of MSK’s leading-edge cancer clinical trials and protocols are now being offered to cancer patients who receive care within the Institute.

That means promising and potentially groundbreaking advances in cancer research and treatment are being made available to patients without requiring them to go to New York City, where MSK is located and where previously patients had to travel to gain access to MSK’s world-renowned bank of trials and protocols.

The rollout of MSK clinical trials to patients within Hartford HealthCare is a cornerstone the Institute’s membership in the Alliance. As of July 2016, the Institute had made MSK-originated clinical trials and research protocols available to patients who are being cared at any of the five cancer centers that make up the Cancer Institute – Hartford Hospital, Backus Hospital, Windham Hospital, The Hospital of Central Connecticut and MidState Medical Center. Additional trials and studies are expected to be opened to patients over the next several months.

The MSK trials are being made available in addition to a wide array of promising trials and research protocols now being offered to patients as part of the Institute’s Cancer Clinical Research Office, which are conducted by physicians and research specialists at the various cancer centers within the Institute.

“Our goal is to add to our existing portfolio of studies and to offer a comprehensive array of clinical trials for patients with common and uncommon cancers treated at the Hartford HealthCare Cancer Institute,” said Ellen Dornelas, PhD, Director of the Cancer Clinical Research Office.

What is the "Cancer Moon Shot"?

Have you heard of the cancer moonshot? "We've been told by the federal government that the goal is to do what you are doing anyway, but do it a lot faster," says Dr. Peter Wu, Senior VP, Hartford HealthCare & Physician-in-Chief, Hartford HealthCare Cancer Institute. "So, instead of taking ten years to accomplish something, figure out how to do it in five."


  • Lung Cancer EA5142

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial that studies how well Nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.

  • Lung Cancer E4512

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) that studies how well Crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK).

  • Lung Cancer Alchemist A081105

    April 27, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III (Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely) trial that studies how well Erlotinib Hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery.

  • Lung Cancer Alchemist A151216

    April 27, 2017

    This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been, or will be removed by surgery.

  • Gynecologic Cancer 274

    April 26, 2017

    This trial studies how well giving Cisplatin and radiation therapy together with or without Carboplatin and Paclitaxel works in treating patients with cervical cancer has spread from where it started to nearby tissue or lymph nodes.

  • Head/Neck Cancer 0920

    April 26, 2017

    This study focuses on treating patients who have undergone surgery for head and neck cancer that has spread to nearby tissues or organs.

  • Gynecologic Cancer 286B

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial studies how well Paclitaxel, Carboplatin, and Metformin Hydrochloride works and compares it to Paclitaxel, Carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back.

  • Gynecologic Cancer NRG-005

    April 26, 2017

    This trial studies how well Cediranib Maleate and Olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory).

  • Gynecologic Cancer NRG-004

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase III trial that studies olaparib or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Phase III trials are new treatments that have worked well in a small number of patients with a disease.

  • Gynecologic Cancer GOG 281

    April 26, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II/III trial that studies how well Trametinib works and compares it to standard treatment with either Letrozole, Tamoxifen citrate, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, or Topotecan hydrochloride in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back, become worse, or spread to other parts of the body.

  • Gynecologic Cancer ET743-OVC-3006

    April 26, 2017

    The purpose of this study is to assess the efficacy and safety of Trabectedin+DOXIL as a third-line chemotherapy regimen in patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who received 2 previous lines of platinum-based chemotherapy.

  • Gynecologic Cancer 3005/ABBVIE M13-694

    April 26, 2017

    The focus of this study is to evaluate the efficacy, safety, and tolerability of Veliparib in women with previously untreated, Stage III or IV (cancer which has spread from the site of the primary (original) tumor only to surrounding tissue, lymph nodes, or the development of secondary malignant growths at a distance from a primary site of cancer), high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  • Gynecologic Cancer 264

    April 26, 2017

    This trial studies Paclitaxel and Carboplatin to see how well they work compared with Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in treating patients with sex cord-ovarian stromal tumors (gastrointestinal) that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent).

  • Colorectal Cancer NRG GI-002

    April 11, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) trial studies how well Veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started, to nearby tissue or lymph nodes (locally advanced).

  • Colorectal Cancer N1048/RTOG 1271

    April 11, 2017

    The purpose of this study is to compare the effects, both good and bad, of the standard treatment of chemotherapy and radiation to chemotherapy. The study uses a combination regimen known as FOLFOX, (the drugs 5-Fluorouracil (5-FU), Oxaliplatin and Leucovorin) and selective use of the standard treatment, depending on response to the FOLFOX. The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.

  • Pancreatic Cancer RTOG 0848

    April 11, 2017

    This trial studies Gemcitabine Hydrochloride with or without Erlotinib Hydrochloride, followed by the same chemotherapy regimen with or without radiation therapy, and Capecitabine or Fluorouracil in treating patients with pancreatic cancer that was removed by surgery. Chemotherapy drugs used, such as Gemcitabine Hydrochloride, Capecitabine, and Fluorouracil, work in different ways to stop the growth of tumor cells. The drugs work either by killing the cells, stopping them from dividing, or by stopping them from spreading.

  • Breast Cancer ECOG E2112

    April 11, 2017

    High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Endocrine/Hormone therapy using Exemestane may fight breast cancer by lowering the amount of estrogen the body makes or interferes with the effects. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether Exemestane is more effective with or without Entinostat in treating breast cancer.

  • Breast Cancer BR003

    April 11, 2017

    Estrogen receptors and progesterone receptors are receptors that may be found in breast cancer cells. Drugs used in chemotherapy, such as Doxorubicin Hydrochloride, Cyclophosphamide, Paclitaxel, and Carboplatin, work in different ways to stop the growth of tumor cells. They work either by killing the cells, stopping cells from dividing, or by stopping cells from spreading. It is not yet known whether Doxorubicin Hydrochloride and Cyclophosphamide is more effective when followed by Paclitaxel alone or Paclitaxel and Carboplatin in treating triple-negative breast cancer.

  • Breast Cancer SWOG S1207

    April 11, 2017

    High amounts of estrogen (primary female hormone) can cause the growth of breast cancer cells. Hormone therapy using certain treatments may fight breast cancer, by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether hormone therapy is more effective when given with or without Everolimus in treating breast cancer.

  • Breast Cancer B-51

    April 10, 2017

    This trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have already undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

  • Breast Cancer 16-073 PALLAS

    February 08, 2017

    A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer

  • Gynecologic Cancer (Negative Pressure Wound Therapy in Post-Operative Incision Management) 15-309

    February 08, 2017

    The purpose of this study is to compare any good and bad effects of using the Prevena Incision Management System to using the usual standard dry gauze approach. The Prevena Incision Management System is a type of Negative Pressure Wound Therapy (NPWT). NPWT is a portable vacuum device made of a sponge-like foam that is applied over your incision to help draw fluid and debris out after surgery.

  • Gynecologic Cancer (HIPEC) 12-275

    January 03, 2017

    This clinical trial aims to determine the most effective method for fighting gynecologic cancer. Patients who have had a first recurrence of ovarian, fallopian tube, or primary peritoneal cancer that initially responded to platinum-based therapy and which returned more than 6 and less than 30 months after completing that therapy are eligible for this study.

  • Breast Cancer 15-307

    February 08, 2017

    Feasibility study of adjuvant enzalutamide for the treatment of early stage AR(+) triple negative breast cancer.

  • Targeted Teachable Moment Intervention Study

    January 03, 2017

    Targeted Teachable Moment Intervention Study

  • Bladder Cancer 15-291

    January 03, 2017

    Bladder cancers that invade the muscle wall of the bladder have a high risk of returning. Patients with these cancers typically have their bladders removed and are then monitored to see if the cancer comes back. In this study, researchers want to see if the drug atezolizumab can reduce the risk of cancer recurrence after bladder removal surgery for muscle-invasive bladder cancer.

  • Head/Neck Cancer 15-245

    January 03, 2017

    The treatment of head and neck cancers can sometimes leave survivors with problems such as dry mouth, difficulty swallowing, or other long-term side effects that may affect their quality of life. Researchers are interested in learning more about how survivors of head and neck cancers feel after their treatment is completed.

  • Lung Cancer RTOG-1306

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer.

  • Lung Cancer SWOG-1400

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned (by chance) to this screening and multi-sub-study phase II/III trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.

  • Localized Spine Metastasis 0631

    May 09, 2017

    Eligible patients who enroll in the study will be randomly assigned to this phase II/III trial studying how well image-guided radiosurgery or stereotactic body radiation therapy works and compares it to external-beam radiation therapy in treating patients with localized spine metastasis.

  • Bio Specimens (GRAIL)

    May 09, 2017

    This is a prospective, multi-center, observational study with collection of de-identified bio specimens and clinical data from at least 10,000 participants from clinical networks in the United States.

  • Yoga for Cancer Survivors and Patients

    July 26, 2017

    If you are a patient at the Hartford HealthCare Cancer Institute at Hartford Hospital, or a patient with a musculoskeletal condition and a cancer history being seen through the Hartford HealthCare Bone & Joint Institute, you may be eligible for a research study investigating the benefits of yoga on mobility and quality of life.

Cancer Care


Cancer Clinical Research Office - Open Studies Update

View the latest open studies being conducted by the Cancer Clinical Research Office.

Click Here to View


ClinicalTrials.gov

View research studies on clinicaltrials.gov that are currently recruiting volunteers to participate.

Click Here to View